Injectable Multiple Sclerosis Medications

A Patient Survey of Factors Associated with Injection-Site Reactions

Thomas M. Stewart, JD, MS, PA-C; Zung Vu Tran, PhD

Although injection-site reactions (ISRs) occur with US Food and Drug Administration-approved injectable disease-modifying therapies (DMTs) for multiple sclerosis, there are currently few reports of real-world data on ISR management strategies or possible correlations between ISRs and patient demographics, disease characteristics, and missed injections. Patient-reported data on the use of DMTs, patient demographic and disease characteristics, missed injections, and ISR reduction strategies were collected via e-mail, a patient registry (www.ms-cam.org), and a Web-based survey. Of the 1380 respondents, 1201 (87%) indicated that they had used injectable DMTs, of whom 377 (31%) had used intramuscular (IM) interferon beta-1a (IFN\beta-1a), 172 (14%) had used subcutaneous (SC) IFN β -1a, 183 (15%) had used SC IFN β -1b, and 469 (39%) had used glatiramer acetate (GA). The majority of respondents were older (73% were \geq 40 years), female (79%), married or living with a partner (72%), white (94%), and nonsmoking (82%). Injection-site reaction incidence, grouped according to severity, varied among DMTs, with IM IFN β -1a causing significantly (P < .001) fewer mild, moderate, or severe ISRs than the other therapies. Female sex and younger age were significantly (P < .05) associated with more moderate ISRs among users of IM IFN β -1a, SC IFN β -1b, and GA. Nonwhites reported severe ISRs more often than whites. For all DMTs injection-site massage and avoidance of sensitive sites were the most frequently used strategies to minimize ISRs. These data may help identify patients with characteristics associated with a higher risk for ISRs, allowing health-care professionals to provide anticipatory guidance to patients at risk for decreased adherence or discontinuation. Int J MS Care. 2012;14:46-53.

Between 1993 and 2002, four injectable diseasemodifying therapies (DMTs) were approved by the US Food and Drug Administration (FDA) for use in multiple sclerosis (MS) therapy: subcutaneous interferon beta-1b (SC IFNβ-1b; Betaseron, Bayer HealthCare Pharmaceuticals, Wayne, NJ), intramuscular (IM) IFNβ-1a (Avonex, Biogen Idec, Inc, Cambridge, MA), SC IFNβ-1a (Rebif, Serono, Inc, Rockland, MA), and SC glatiramer acetate (GA; Copaxone, Teva Neuroscience, Inc, Kansas City, MO).¹⁻⁴ A fifth injectable DMT (SC IFNβ-1b; Extavia, Novartis Pharmaceuticals Corp, East Hanover, NJ) received FDA

From the Rocky Mountain MS Center, Westminster, CO, USA (TMS), and the Department of Biostatistics & Informatics, Colorado School of Public Health, University of Colorado Anschutz Medical Campus, Aurora, CO, USA (ZVT). *Correspondence:* Thomas M. Stewart, JD, MS, PA-C, 8845 Wagner St., Westminster, CO approval in 2009, after this study was completed.⁵ Multiple clinical trials have shown that treatment with these injectable DMTs reduces the frequency of relapses and slows disease progression.⁶⁻⁹ Although the MS treatment armamentarium is changing with the addition of infused and oral therapies that have recently become available or will be available soon, injectable DMTs remain critical in the treatment of this disease.

One limitation of injectable DMT use for MS is the relatively high rate of treatment discontinuation, estimated to range from 24% to 40% over periods of 2 to 5 years.¹⁰⁻¹³ Among the patient-provided reasons for discontinuing therapy are the side effects of DMTs, specifically injection-site reactions (ISRs). In one report, the primary reasons for discontinuation among the 14% of patients who discontinued IFN β therapy after experiencing associated side effects were ISRs (16%),

(21%).¹¹ Another study found that among patients taking GA, ISRs were the most important side effect leading to discontinuation.¹⁴ Skin reactions influence not only discontinuation rates, but also adherence rates. Indeed, approximately 12% of missed injections may be related to pain at the injection site or other skin reactions.¹⁴ Not surprisingly, skin reactions are less common and appear to be less likely to cause discontinuation in users of the IM injectable therapy.^{1-5,14,15}

Injection-site reactions as a side effect of injectable DMTs have important implications for both discontinuation and adherence. However, few large patient surveys have reported effective strategies for managing ISRs. Moreover, little is known about the relationships between ISRs and patient demographic variables, disease characteristics, and the frequency of missed injections.

Methods

Study Design

Self-reported patient data on ISR occurrence and use of injectable DMTs were collected using e-mail, a patient registry (www.ms-cam.org), and a Web-based survey instrument. The observational online survey collected descriptive information regarding the use of injectable DMTs, ISRs, disease characteristics, and how respondents with MS addressed the challenges presented by DMT-associated ISRs. For the purposes of this study, the population of interest was patients with MS who were using injectable DMTs. However, given that the respondents were from a self-selected registry that may not be completely representative of this population of interest, any generalizations based on the results should take account of this limitation.

Data Collection

Data were collected from a registry of patients with MS that has been maintained by the Rocky Mountain MS Center since June 2000. At the time of the reported survey, there were approximately 18,000 individuals with self-reported MS in the registry. This registry contains e-mail addresses and related unique, anonymous identifiers in a privately held, protected file. Individual patient participants also are given the opportunity to create passwords so that they can log into the server. These methods of data collection ensure both patient anonymity and secure information transfer and have previously been described in detail.¹⁶

MS registry participants were recruited through a

Center (www.mscenter.org) and National Multiple Sclerosis Society (www.nationalmssociety.org) websites. To a lesser extent, patients also learned about this registry through in-office clinic visits or by attending programs presented by clinicians affiliated with the Rocky Mountain MS Center. Typically, registrants were referred to www.ms-cam.org for MS-specific information pertaining to an evidence-based approach to integrative medicine. Thus, it is likely that users registered at www. ms-cam.org to gain access to such information and to participate in survey research. Because the results of Rocky Mountain MS Center surveys are made available to MS registry participants, the opportunity to learn about the experiences of others with MS is an incentive for patients to register. All data collected using patient self-reports and responses from individual registrants remain anonymous.

This Multiple Sclerosis-Injection Site Reaction (MS-ISR) survey was initiated through e-mails sent to the subset of registered patients who had expressed interest in participating in surveys and also demonstrated an ability to complete administered surveys. The methodology and specific content of the MS-ISR survey were approved by a local institutional review board. A subset of these data was previously presented in a preliminary format.¹⁷ The MS-ISR survey instrument was designed by the authors and carefully reviewed by clinicians subspecializing in MS, although it did not undergo preliminary patient testing and evaluation prior to its administration. Patients who received regular medical care and who self-identified as having used injectable DMTs were asked about a number of other factors that might contribute to their ISRs, such as injectable medication used and time on current medication. Respondents were also asked to indicate whether they had tried any of ten possible strategies, compiled from multiple sources as well as the authors' own clinical experience, to prevent or relieve their ISRs. In addition, respondents were asked about their use of autoinjectors. For the purpose of this survey, no attempt was made to validate the effectiveness of any of these strategies. Disability data were also collected using the Patient-Determined Disease Steps model.^{18,19}

Although ISRs are universally recognized to be an issue with the use of injectable DMTs for MS, the term currently has no standard definition, nor is there any widely accepted method for grading the severity of ISRs. In the present survey, respondents were asked to

ISRs (rarely, sometimes, or often) and the seriousness of these ISRs according to three categories: 1) "mild" usually transient and involving heat, redness, swelling, and/or bruising; 2) "moderate"—possibly not transient, involving discomfort, and involving itching, pain, lumps, dimpling, and/or skin sores; and 3) "severe" including scabs, crusting around wound, infection, and/ or necrosis. The categories mild, moderate, and severe were not mutually exclusive, as respondents could have experienced one or more of the three different ISR categories. Thus, individual patients may be counted in more than one ISR category depending on their individual symptoms.

Statistical Analyses

All analyses were performed using SPSS, version 17 (SPSS, Inc, Chicago, IL). Prior to analyses, data were examined for data entry and coding errors. Out-of-range and statistical outliers were also checked and, where possible, corrected. If data could not be corrected, they were treated as missing. Descriptive statistics were generated, including medians, means, standard deviations, minimums, and maximums; categorical variables were expressed as percentages. To assess possible associations between two variables, Pearson correlation coefficients were calculated for interval data, Spearman rank correlation coefficients were calculated for ordinal data, and point-biserial correlation coefficients were calculated for dichotomous variables. An independent-sample t test (or its nonparametric counterpart) was used to compare means between two groups, and a dependent-sample t test (or its nonparametric counterpart) was used to compare two means within a group. A one-way analysis of variance test, with or without repeated measures, was used to compare more than two means. Post hoc, pairwise multiple comparisons were performed using the Bonferroni adjustment. Chi-square analysis was used to assess differences in percentages or proportions.²⁰

Results

Data for the MS-ISR survey were collected in 2007, with a total of 1380 eligible patients with MS providing responses. However, 179 (13%) respondents did not provide information on DMT use, leaving 1201 responses for analysis. Not all respondents answered all questions; thus, the number of patient responses to each question is a subset of the total number of 1201 useful

Analysis of patient-reported ISRs showed significant associations between use of injectable DMTs and reports of ISRs, induced discomfort following injection, and severe ISRs (Table 2). Intramuscular IFNβ-1a use was associated with significantly fewer reported ISRs than the other DMTs for all three severity categories, with 82% of patients receiving IM IFNβ-1a experiencing mild side effects (P < .001), 73% experiencing moderate side effects (P < .001), and 2% experiencing severe side effects (P < .001). Also, users of IM IFN β -1a missed fewer injections because of skin reactions than users of the other DMTs. In comparison, patients receiving SC IFNβ-1a, SC IFNβ-1b, or GA reported a higher incidence of mild (99%, 94%, and 98%, respectively), moderate (91%, 78%, and 90%, respectively), and severe (7%, 15%, and 9%, respectively) ISRs.

For IM IFN β -1a, SC IFN β -1b, and GA, female sex and younger age were significantly associated with moderate ISRs, including perceptions of discomfort. Female users of IM IFN β -1a and GA reported more transient ISRs than did male users (Table 3). Also, nonwhite patients receiving IM IFN β -1a, SC IFN β -1a, and GA reported more severe reactions than whites. Smoking, therapy duration, and disability level were not significantly associated with any category (transient, discomfort-causing, or serious) of skin reactions.

The specific strategies used to manage ISRs were similar among users of each of the four injectable DMTs, with a group of six management strategies constituting the top five strategies for all four injectable DMTs (Table 4). The top two management strategies, injection-site massage and avoidance of sensitive injection sites, were identical across all four injectable DMTs. In addition, of the 55% of all respondents who used SC autoinjectors, 24% reported that autoinjectors ameliorated their ISRs.

Discussion

Multiple studies and clinical experience have demonstrated that ISRs are a common side effect of injectable DMTs.²¹⁻²³ It is also clear from the present data set and multiple other reported studies that less severe ISRs are reported with IM IFN β -1a than with the other injectable DMTs for MS.^{14,24,25} Our findings on the frequency of ISRs (Table 2) generally conform with what has previously been reported and underscore the deleterious effect that ISRs have on treatment continuation and

AnatocFor the constraint of the constrai	Variable	Number	Percentage	Variable	Number	Percentage
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Humber	rereentuge	MS provider	Humber	rereentuge
Ato $j L 2$ $j T$ Neurologist's office $g P 2$ $j T$ Gender Primary-care physician 31 3 Male 250 21 Other 17 1 Fernale 946 79 Implementation 31 3 Maried/living with partner 862 72 GA 469 39 Divorced 133 11 Time on current DMT, y 183 15 Maried/living with partner 862 72 GA 469 39 Divorced 133 11 Time on current DMT, y 183 15 Maried vithe 1122 94 >2 278 74 Sonking status 73 18 SC [FNP-1a 22 29 17 No 974 82 SC [FNP-1a 22 20 63 Gacourd elegree 206 17 >2 20 63 34 Gacourd elegree 206 17 >2	<10	377	27	MS center or MS clinic	261	22
Letto Doto Primary-care physician 31 3 Male 250 21 Primary-care physician 31 3 Male 250 21 Other 17 1 Fenale 946 946 946 946 946 946 Marital staus Injectable DMT Injectable DMT 172 14 Marited/living with partner 862 72 GA 469 39 Divorced 133 11 Time on current DMT, y IMitPhy-1a 83 15 Maried/living with partner 862 72 GA 469 39 Divorced 133 11 1 Time on current DMT, y IMitPhy-1a 83 15 Withe 1122 94 22 27 28 74 Sonoking staus 2 2 29 17 83 83 Yes 217 18 SC [FNβ-1b 31 83 84 Keatalist leystoning staus 2 2 120 66 64 64 64 <td><<u>10</u></td> <td>878</td> <td>73</td> <td>Neurologist's office</td> <td>892</td> <td>74</td>	< <u>10</u>	878	73	Neurologist's office	892	74
	≥40 Condor	070	75	Primary-care physician	31	3
Marie 2.10 2.1 Injectable DMT Fernale 946 79 Injectable DMT Maried/living with partner 862 72 GA 377 31 Single 178 15 SC [FN]B-1a 172 14 Maried/living with partner 862 72 GA 469 39 Divorced 133 11 Time on current DMT, y IM [FN]B-1a - Race - 2 99 26 - - 2 99 26 Single jatus 75 6 - - 2 99 26 Single jatus - - 2 143 83 34 Yes 217 18 SC [FN]B-1b - - 2 143 83 Yes 217 18 SC [FN]B-1b - 2 29 163 34 Less than high school 5 <1	Malo	250	21	Other	17	1
Freinae 940 79 IM [FNβ-1a 377 31 Marital staus Single 178 15 SC [FNβ-1b 183 15 Marited/living with partner 862 72 GA 469 39 Divorced 133 11 Time on current DMT, y 143 15 Marited status 23 2 IM [FNβ-1a 72 14 Solowed 23 2 IM [FNβ-1a 72 14 Race 2 99 26 White 1122 94 ≥2 278 74 Nonwhite 75 6 SC [FNβ-1a - 2 143 83 Yes 217 18 ≥2 29 175 5 17 22 29 17 8 22 120 66 34 22 120 66 34 22 120 66 34 22 120 16 16 22 120<	Formale	230	21	Injectable DMT		
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Female Marital status	940	79	IM IFNβ-1a	377	31
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		170	1.5	SC IFNβ-1a	172	14
$\begin{array}{l c c c c c c c c c c c c c c c c c c c$	Single	1/6	15	SC IFNβ-1b	183	15
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Married/living with partner	862	12	GA	469	39
Wide 23 2 IM [FNp-1a Race	Divorced	133	11	Time on current DMT, y		
kace <2 99 26 White 1122 94 ≥ 2 278 74 Nonwhite 75 6 SC (FNβ-1a <2 29 17 Smoking status ≥ 2 23 29 17 83 22 29 17 No 974 82 <2 63 34 22 26 33 34 Less than high school 5 <1 GA ≥ 2 120 66 Less than high school 295 25 <2 175 37 Associate degree 294 25 22 294 63 Bachelor degree 384 32 Did ISRs cause missed injections? $Tress$ 78 78 Regional residence Yes 12^b 4 83 81 $5C$ (FNβ-1a $Tress$ 32 19 81 81 $5C$ (FNβ-1a $Tress$ 32 19 81 81 81 $5C$ (FNβ-1a $Tress$ 78	Widowed	23	2	IM IFNβ-1a		
White 1122 94 52 278 74 75 6 $5C$ [FNβ-1a Smoking staus -2 143 83 Yes 217 18 22 29 17 No 974 82 22 143 83 Zeta 29 17 82 22 120 66 Education level -2 63 34 22 137 37 Less than high school 295 25 <2 175 37 Associate degree 294 25 IM IFNP-1a 74 22 63 34 Craduate degree 294 25 IM IFNP-1a 74 22 294 63 Graduate degree 294 25 IM IFNP-1a 74 74 74 Regional residence Yes 128 74 No 138 81 Southern US 256 21 Yes 13 8 74	Race			<2	99	26
Nomhite 75 6 $SC [FN]F1^{a}$ Smoking status -2 143 83 Yes 217 18 ≥ 2 29 17 No 974 82 ≥ 2 29 17 No 974 82 ≥ 2 29 17 Less than high school 5 <1	White	1122	94		278	/4
Smoking status 22 143 63 Yes 217 18 22 29 17 No 974 82 22 29 17 Education level 22 63 34 Less than high school 5 <1 GA 22 120 66 High school 295 25 <2 175 37 Associate degree 206 17 ≥ 2 294 63 Bachelor degree 384 32 Did ISRs cause missed injections? T Graduate degree 294 25 IM IFNβ-1a Yes 32 19 Regional residence Yes 32 19 No 138 81 Southern US 256 21 Yes 32 19 Southern US 289 24 SC IFNβ-1a Yes 38 81 Central Canada 11 1 Yes 38 8 SC IFNβ-1b Yes	Nonwhite	75	6	SC IFNB-Ta	140	0.2
Yes 217 18 22 23 17 No 974 82 SC [FNβ-1b < 22 63 34 Education level ≥ 2 120 66 6A ~ 22 120 66 High school 295 25 < 2 175 37 35 37 Associate degree 206 17 ≥ 2 294 63 34 Graduate degree 294 25 IM IFNβ-1a Yes 12b 4 Regional residence Yes 12b 4 No 295 96 Southern US 256 21 SC IFNβ-1a Yes 32 19 Southern US 256 21 SC IFNβ-1a Yes 32 19 Southern US 289 24 SC IFNβ-1b 138 81 S2 160 92 Western Canada 10 1 No 160 92 92 S2 17 No 384 84 Prosider of injectable DMT No 384 84	Smoking status			<2	143	83 17
No 974 82 $< 2^{1}$ 63 34 Education level 2 63 34 Less than high school 5 <1	Yes	217	18	SC IENIR 16	29	17
Education level 22 120 63 54 Less than high school 5 <1	No	974	82	-2	63	34
Less than high school 5 <1 GA Its Its< <thits< <="" td=""><td>Education level</td><td></td><td></td><td>>2</td><td>120</td><td>66</td></thits<>	Education level			>2	120	66
High school29525<217537Associate degree20617 ≥ 2 29463Bachelor degree38432Did ISRs cause missed injections?12b4Regional residenceYes12b44Eastern US40434No29596Midwestern US25621SC IFNβ-1a12b4Southern US15613Yes3219No13828924SC IFNβ-1b13881Eastern Canada111Yes138Central Canada101No16092Western US585Yes7316Dipment statusNo160921116Ves70759Provider of injectable DMT12311No48241instruction12311No48241Nurse0ffice1079Mid disability41635Office1079No disability16113Pharmaceutical33929Late cane847MS specialist19117Bilateral support696Mean (SD)RangeWheelchair-bound615Years since symptom onset15.0 (9.2)3-52Unclassifiable292Years since MS diagnosis10.6 (6.5)3-56	Less than high school	5	<1	GA	120	00
Associate degree 206 17 ≥ 2 294 63 Bachelor degree 384 32 Did ISRs cause missed injections? Did ISRs cause missed injections? IMI IFNβ-1a Yes 12 ^b 4 Regional residence Yes 12 ^b 4 No 295 96 Midwestern US 256 21 Yes 32 19 Southern US 156 13 Yes 32 19 Western US 289 24 SC IFNβ-1a Testern Canada 11 1 Yes 13 8 Central Canada 10 1 No 160 92 24 SC IFNβ-1b Testern Canada 17 1 GA 9 384 84 84 Other 58 5 Yes 73 16 16 92 13 8 <1	High school	295	25	<2	175	37
Bachelor degree 384 32 Did ISRs cause missed injections? Graduate degree 294 25 IM IFN β -1a Yes 12 ^b 4 Regional residence Yes 12 ^b 4 No 295 96 Midwestern US 256 21 Yes 32 19 Southern US 156 13 No 138 81 Western US 289 24 SC IFN β -1a Yes 32 19 Keatern Canada 11 1 Yes 13 8 Central Canada 10 1 No 160 92 Western Canada 17 1 GA 73 16 Employment status Yes 73 16 No 384 84 Yes 707 59 Yes 73 16 No disability 204 17 Neurologist 123 11 Neid disability 161 13 Physician (not neurologist)<	Associate degree	206	17	≥2	294	63
Graduate degree 294 25 IM IFNβ-1a Regional residence Yes 12^b 4 Eastern US 404 34 No 295 96 Midwestern US 256 21 SC IFNβ-1a Yes 32 19 Southern US 156 13 Yes 32 19 Western US 289 24 SC IFNβ-1b 81 81 Eastern Canada 11 1 Yes 13 8 Central Canada 10 1 No 160 92 Western Canada 17 1 GA 73 16 Other 58 5 Yes 73 16 No 482 41 instruction Neurologist 123 11 Disease step ^a 707 59 Provider of injectable DMT Nurse 0ffice 107 9 Mid disability 204 17 Nurse 0ffice 107 9 <td>Bachelor degree</td> <td>384</td> <td>32</td> <td>Did ISRs cause missed injections?</td> <td></td> <td></td>	Bachelor degree	384	32	Did ISRs cause missed injections?		
Regional residence Yes 12^b 4 Eastern US 404 34 No 295 96 Midwestern US 256 21 Yes 32 19 Southern US 156 13 No 138 81 Western US 289 24 SC IFNβ-1a 7 1 8 Central Canada 10 1 No 160 92 Western Canada 17 1 GA 7 7 6 Other 58 5 Yes 73 16 Employment status 707 59 Provider of injectable DMT 1 No 482 41 Nurse 1 1 Disease step ^a No 123 11 1 Mild disability 161 13 Nurse 107 9 Moderate disability 161 13 107 9 Mid disability 161 13 Pharmaceutical 339 29 Late cane 84 7 MS specialist	Graduate degree	294	25	IM IFNβ-1a		
Eastern US 404 34 No 295 96 Midwestern US 256 21 SC IFNβ-1a 7 19 Southern US 156 13 Yes 32 19 Western US 289 24 No 138 81 Eastern Canada 11 1 Yes 13 8 Central Canada 10 1 No 160 92 Western Canada 17 1 GA 7 16 Other 58 5 Yes 73 16 Employment status 707 59 Provider of injectable DMT 7 10 Disease step ³ No 482 41 Nurse 11 11 Nurse 123 11 Mid disability 204 17 Nurse 123 11 Nurse 107 9 Moderate disability 161 13 Mid isability 133 32 29 <t< td=""><td>Regional residence</td><td></td><td></td><td>Yes</td><td>12^b</td><td>4</td></t<>	Regional residence			Yes	12 ^b	4
Midwestern US25621SC IFNβ-1aSouthern US15613Yes3219Western US28924No13881Eastern Canada111Yes138Central Canada101No16092Western Canada171GA7316Other585Yes7316Employment status70759Provider of injectable DMT1No48241instruction12311Disease stepa7515Physician (not neurologist)8<1	Eastern US	404	34	No	295	96
Southern US15613Yes3219Western US28924No13881Eastern Canada111Yes138Central Canada101No16092Western Canada171GA16092Other585Yes7316Employment status70759Provider of injectable DMT12311No48241instructionNeurologist12311Disease stepa70759Physician (not neurologist)8<1	Midwestern US	256	21	SC IFNβ-1a		
Western US28924No13881Eastern Canada111 SC IFN β -1bYes138Central Canada101No16092Western Canada171GA	Southern US	156	13	Yes	32	19
Eastern Canada 11 1 Yes 13 8 Central Canada 10 1 No 160 92 Western Canada 17 1 GA 0 160 92 Western Canada 17 1 GA 0 160 92 Other 58 5 Yes 73 16 Employment status 707 59 Provider of injectable DMT 100 11 No 482 41 instruction 123 11 Disease step ^a No 482 41 Nurse 0 123 11 No disability 204 17 Nurse 0 107 9 Mid disability 416 35 Office 107 9 Moderate disability 161 13 Pharmaceutical 339 29 Late cane 84 7 MS specialist 191 17 Bilateral support 69 6 Mean (SD) Range Wheelchair-bound 61 5 Yea	Western US	289	24	No	138	81
Central Canada101Yes138Central Canada101No16092Western Canada171GA7Other585Yes7316Employment status70759Provider of injectable DMT84Yes70759Provider of injectable DMT12311Disease stepa16113Nurse12311No disability20417Nurse0ffice1079Moderate disability1611313Physician (not neurologist)8<1	Eastern Canada	11	1	SC IFNB-16	10	0
Western Canada171GAOther585Yes7316Employment status70759No38484Yes70759Provider of injectable DMTinstructionDisease stepa8241instruction12311No disability20417Nurse1079Mild disability41635Office1079Moderate disability16113Home health care38734Early cane17515Pharmaceutical33929Late cane847MS specialist19117Bilateral support696Years since symptom onset15.0 (9.2)3-52Unclassifiable292Years since MS diagnosis10.6 (6.5)3-56	Central Canada	10	1	Yes	13	8 02
Western canada171716Other585Yes7316Employment status70759No38484Yes70759Provider of injectable DMTinstructionNo48241instructionNeurologist12311Disease stepa7316No8<1	Western Canada	17	1		160	92
Employment status70759No38484Yes70759Provider of injectable DMTinstructionNo48241instructionNeurologist12311Disease stepa11Physician (not neurologist)8<1	Other	58	5		73	16
Yes70759Provider of injectable DMTNo48241Disease stepaNo disability20417No disability20417Mild disability41635Moderate disability16113Early cane17515Late cane847Bilateral support69Wheelchair-bound615Unclassifiable292Yes292Yes29Yes29Yes29Yes29Yes29Yes29Yes29Yes29Yes29Years since MS diagnosis10.6 (6.5)Years since MS diagnosis10.6 (6.5)	Employment status	50	5	No	384	84
No48241instructionDisease stepa20417Neurologist12311No disability20417Neurologist8<1	Vos	707	50	Provider of injectable DMT	501	01
No46241Metrologist12311Disease stepa20417Neurologist12311No disability20417Physician (not neurologist)8<1	No	107	J9 41	instruction		
No disability20417Mild disability41635Moderate disability16113Early cane17515Late cane847Bilateral support696Wheelchair-bound615Unclassifiable292Years since MS diagnosis10.6 (6.5)3-52	Disease stopa	402	41	Neurologist	123	11
No disability20417Mild disability41635Moderate disability16113Early cane17515Late cane847Bilateral support696Wheelchair-bound615Unclassifiable29292Years since MS diagnosis10.6 (6.5)3435363738393939343393434339343393433934343536363738393939393030303031313233933934350351351352352353354355355	No disability	204	17	Physician (not neurologist)	8	<1
Wild disability41655Office1079Moderate disability16113Home health care38734Early cane17515Pharmaceutical33929Late cane847MS specialist19117Bilateral support696Mean (SD)RangeWheelchair-bound615Years since symptom onset15.0 (9.2)3-52Unclassifiable292Years since MS diagnosis10.6 (6.5)3-56	NU UISADIIILY	204	1/	Nurse		
Woderate disability16113Home health care38734Early cane17515Pharmaceutical33929Late cane847MS specialist19117Bilateral support696Mean (SD)RangeWheelchair-bound615Years since symptom onset15.0 (9.2)3-52Unclassifiable292Years since MS diagnosis10.6 (6.5)3-56		416	33 12	Office	107	9
Larly cane1/515Pharmaceutical33929Late cane847MS specialist19117Bilateral support696Mean (SD)RangeWheelchair-bound615Years since symptom onset15.0 (9.2)3-52Unclassifiable292Years since MS diagnosis10.6 (6.5)3-56	woderate disability	161	13	Home health care	387	34
Late cane84/MS specialist19117Bilateral support696Mean (SD)RangeWheelchair-bound615Years since symptom onset15.0 (9.2)3–52Unclassifiable292Years since MS diagnosis10.6 (6.5)3–56	Early cane	1/5	15	Pharmaceutical	339	29
Bilateral support696Mean (SD)RangeWheelchair-bound615Years since symptom onset15.0 (9.2)3–52Unclassifiable292Years since MS diagnosis10.6 (6.5)3–56	Late cane	84	7	MS specialist	191	17
Wheelchair-bound 61 5 Years since symptom onset 15.0 (9.2) 3–52 Unclassifiable 29 2 Years since MS diagnosis 10.6 (6.5) 3–56	Bilateral support	69	6		Mean (SD)	Range
Unclassifiable292Years since MS diagnosis10.6 (6.5)3–56	Wheelchair-bound	61	5	Years since symptom onset	15.0 (9.2)	3–52
	Unclassifiable	29	2	Years since MS diagnosis	10.6 (6.5)	3–56

Table 1. Demographics for 1201 respondents using one of the four FDA-approved injectable DMTs

Abbreviations: DMT, disease-modifying therapy; FDA, US Food and Drug Administration; GA, glatiramer acetate; IFNβ-1a, interferon beta-1a; IFNβ-1b, interferon beta-1b; IM, intramuscular; ISR, injection-site reaction; MS, multiple sclerosis; SC, subcutaneous; SD, standard deviation. ^aNo disability—functionally normal with no limitations on activity or lifestyle; mild disability—mild signs or symptoms; moderate disability—main feature is a visibly abnormal gait; early cane—uses a cane or other form of unilateral support for greater distances, but can walk at least 25 feet without it; late cane—unable to walk 25 feet without a cane or other form of unilateral support; bilateral support—requires bilateral support to walk 25 feet; wheelchair-bound—essentially confined to wheelchair.

^bP < .001

Δ

DOCKE

Δ

RM

Table 2. Perceived injection-site reaction severity with different DMTs

	Perceived injection-site reaction severity					
DMT	Mild	Moderate	Severe			
IM IFNβ-1a	82%	73%	2%			
	(306/374) ^a	(266/366)ª	(9/364)ª			
SC IFNβ-1a	99%	91%	7%			
	(169/171)	(153/168)	(11/169)			
SC IFNβ-1b	94%	78%	15%			
	(170/181)	(135/174)	(25/170)			
GA	98%	90%	9%			
	(456/465)	(409/455)	(40/449)			

Abbreviations: DMT, disease-modifying therapy; GA, glatiramer acetate; IFN β -1a, interferon beta-1a; IFN β -1b, interferon beta-1b; IM, intramuscular; SC, subcutaneous.

Note: Responses were from patients reporting ever having experienced an ISR while on an injectable DMT. Individual patients may be counted in more than one ISR category depending on their individual symptoms.

^aSignificantly different from other DMTs, P < .001.

tinued study of these side effects and their causes and for continued patient education to alleviate symptoms, maintain compliance, and positively affect long-term MS outcomes.

Regarding associations among demographic characteristics and ISRs, the present results elaborate on previous findings reported by other investigators by identifying new associations and challenging a few previously proposed associations. In accordance with other studies,^{15,27,28} the present data suggest that females report more moderate ISRs than do males. However, this specific finding was not apparent with SC IFNβ-1a, possibly as the result of a ceiling effect, with a high frequency of moderate side effects being reported by almost all users of that drug. This study also revealed two demographic associations that, to our knowledge, have not been previously reported. First, younger patients (<40 years of age) had more frequent complaints of discomfort with injections. Again, this specific association was not apparent with patients receiving SC IFNβ-1a, possi-

Table 3. Perceived transient, discomfort-causing, or serious injection-site reactions by select demographic variables

<u> </u>						
	IM IFNβ-1a			SC IFNβ1a		
Variable	Transient	Discomfort	Serious	Transient	Discomfort	Serious
Sex						
Male	61% (49/80)	62% (49/79)	3% (2/79)	100% (34/34)	91% (29/32)	13% (4/32)
Female	87% (255/292) ^a	76% (216/285) ^b	2% (7/283)	99% (134/136)	91% (123/135)	5% (7/131)
Age, y						
<40	88% (84/95)	98% (84/86)	3% (3/89)	100% (61/61)	95% (58/61)	7% (4/61)
≥40	22% (68/305)	67% (181/269) ^a	3% (8/240)	98% (108/110)	89% (95/107)	7% (7/103)
Smoking						
Yes	83% (57/69)	71% (49/69)	4% (3/69)	100% (23/23)	96% (22/23)	9% (2/23)
No	82% (247/302)	73% (215/294)	2% (6/292)	99% (144/146)	90% (129/143)	6% (9/139)
Disability						
0 or 1	77% (56/73)	75% (54/72)	4% (3/71)	14% (3/22)	80% (20/25)	14% (3/22)
≥2	83% (241/289)	72% (203/282)	2% (6/281)	14% (20/145)	77% (112/146)	14% (20/145)
Therapy						
duration, y						
<2	80% (78/98)	69% (66/95)	4% (4/94)	99% (141/143)	91% (130/143)	7% (10/139)
≥2	83% (228/276)	74% (200/271)	2% (5/270)	100% (28/28)	92% (23/25)	4% (1/25)
Race						
White	83% (285/344)	71% (240/336)	2% (6/334)	99% (154/156)	92% (140/153)	4% (6/149)
Nonwhite	70% (19/27)	85% (23/27)	11% (3/27) ^c	100% (15/15)	87% (13/15)	33% (5/15) ^a

Abbreviations: GA, glatiramer acetate; IFN β -1a, interferon beta-1a; IFN β -1b, interferon beta-1b; IM, intramuscular; SC, subcutaneous. Note: Responses were from patients reporting ever having experienced an injection-site reaction while on an injectable disease-modifying therapy. Individual patients may be counted in more than one injection-site reaction category depending on their individual symptoms. $^{a}P < .001$.

^bP < .05.

DOCKET



Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

